- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06477952
Traitement DRonabinol de l'AOS (DROSA)
Traitement ciblé de l'apnée obstructive du sommeil avec le dronabinol : preuve de concept et essai clinique de phase II
This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.
This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Karen M Lenehan
- Numéro de téléphone: (312) 569-6343
- E-mail: Karen.Lenehan@va.gov
Sauvegarde des contacts de l'étude
- Nom: Bharati Prasad, MD
- Numéro de téléphone: (312) 996-8433
- E-mail: bharati.prasad@va.gov
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Recrutement
- Jesse Brown VA Medical Center, Chicago, IL
-
Contact:
- Howard S Gordon, MD BS
- Numéro de téléphone: (312) 569-7331
- E-mail: howard.gordon2@va.gov
-
Contact:
- Karen M Lenehan
- Numéro de téléphone: (312) 569-6343
- E-mail: Karen.Lenehan@va.gov
-
Chercheur principal:
- Bharati Prasad, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
1. AHI 15-50 per hour on pre-treatment polysomnography
Exclusion Criteria:
-
Positive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
-
Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report
-
History of upper airway surgery for OSA (except adenotonsillectomy)
-
Central or mixed apneas >25% of respiratory events on diagnostic polysomnography
-
Arterial oxygen saturation < 75% for > 5% sleep time on pretreatment polysomnography
-
Body mass index > 45 kilograms per square meter (kg/m2)
-
If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug
-
Active enrollment in a weight loss program
-
Shiftwork within 3 months of enrollment
-
High-risk occupation: commercial driver and pilot
-
Motor vehicle accident or near-miss incident within 1 year of enrollment
-
Current drug or habitual alcohol use or positive urine drug screen
-
Comorbid medical and psychiatric disorders:
- Primary sleep disorders: e.g., narcolepsy, restless legs syndrome
- Uncontrolled mood disorder or a diagnosis of schizophrenia
- Initiation of new antidepressant or antipsychotic medication within 3 months
- Identified as high-risk for suicide in electronic health records
- Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders)
-
Use of sedative-hypnotic medications within 30 days of enrollment
-
Complete blood count or liver function test values more than 1.5 times the upper limit of normal
-
Pregnancy
-
Allergy to cannabinoids or sesame oil
-
Average weekly alcohol consumption of more than 10 servings
-
Participation in other investigational protocols within 30 days of enrollment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Single group
Open label Dronabinol treatment for two weeks. |
Open label Dronabinol treatment for two weeks.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Apnea Hypopnea Index (AHI)
Délai: 2 weeks
|
The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
T<90
Délai: 2 weeks
|
The change in time below 90% oxygen saturation (T<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Psychomotor Vigilance Test (PVT)
Délai: 2 weeks
|
The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol. |
2 weeks
|
|
24-hour Mean Arterial Blood Pressure (BP)
Délai: 2 weeks
|
The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording. |
2 weeks
|
|
Sleep Efficiency
Délai: 2 weeks
|
The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Rapid Eye Movement (REM) Sleep
Délai: 2 weeks
|
The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Slow Wave Sleep
Délai: 2 weeks
|
The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Treatment Satisfaction Questionnaire for Medication (TSQM)
Délai: 2 weeks
|
Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction. |
2 weeks
|
|
Epworth Sleepiness Scale (ESS)
Délai: 2 weeks
|
The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment. ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness. |
2 weeks
|
|
Functional Outcomes of Sleep Questionnaire (FOSQ)
Délai: 2 weeks
|
The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment. FOSQ score ranges from 5-20, with higher scores indicating better functional status. |
2 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
Délai: 2 weeks
|
The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment. The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality. |
2 weeks
|
|
Insomnia Severity Index (ISI)
Délai: 2 weeks
|
The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment. ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance. |
2 weeks
|
|
Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)
Délai: 2 weeks
|
The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment. PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. |
2 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Bharati Prasad, MD, Jesse Brown VA Medical Center, Chicago, IL
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux
- Maladies des voies respiratoires
- Troubles respiratoires
- Troubles du sommeil et de l'éveil
- Apnée
- Troubles du sommeil, intrinsèques
- Dyssomnies
- Syndromes d'apnée du sommeil
- Apnée du sommeil, obstructive
- Produits chimiques organiques
- Hydrocarbures
- Terpènes
- Cannabinoïdes
- Dronabinol
Autres numéros d'identification d'étude
- PULM-011-23F
- 5I01CX002632-02 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .